EW
Edwards Lifesciences Corp
Edwards Lifesciences Corp historical holders
total: 7
Giverny Capital Edwards Lifesciences Corp transactions over time
- Total transactions:
- 30
- New positions:
- 1
- Sold out:
- 1
- Added:
- 21
- Reduced:
- 7
- Held since:
- 2017 Q4
- Held for:
- 29 quarters
- Latest activity:
- 2025 Q1
Francois Rochon has been an institutional investor in Edwards Lifesciences Corp (EW) since 2017 Q4. According to 2026 Q1 report, Francois Rochon doesn't hold any shares. The fund/company first acquired EW in 2017 Q4, initially purchasing 484,713 shares. Since the initial investment, Giverny Capital has made 29 more transactions in this position.
When did Francois Rochon exit their EW position?
Francois Rochon no longer holds Edwards Lifesciences Corp (EW). They sold off their entire position in 2025 Q1, closing out an investment that began in 2017 Q4.
When did Francois Rochon first invest in EW?
Francois Rochon first invested in Edwards Lifesciences Corp (EW) in 2017 Q4 at the reported quarter-end price of $37.57 per share, acquiring 484,713 shares in their initial purchase.
What is Francois Rochon's average cost basis for EW?
Based on historical transaction data, Francois Rochon's estimated cost basis for Edwards Lifesciences Corp (EW) is approximately $48.27 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $48.27
- Weighted AVG sell price:
- $67.91
EW transactions history by Giverny Capital
30 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2025 Q1
|
0.00%
|
0
|
$74.03
|
|
-100% (-257)
|
-0%
|
|
2024 Q4
|
0.00%
|
257
|
$74.03
|
$19,026
|
-99.94% (-446,031)
|
-1.26%
|
|
2024 Q3
|
1.12%
|
446,288
|
$65.99
|
$29,450,545
|
+0.06% (+272)
|
+0%
|
|
2024 Q2
|
1.74%
|
446,016
|
$92.37
|
$41,198,498
|
+0.07% (+298)
|
+0%
|
|
2024 Q1
|
1.73%
|
445,718
|
$95.56
|
$42,592,812
|
+1.09% (+4,812)
|
+0.02%
|
|
2023 Q4
|
1.58%
|
440,906
|
$76.25
|
$33,619,083
|
+0.07% (+304)
|
+0%
|
|
2023 Q3
|
1.66%
|
440,602
|
$69.28
|
$30,524,907
|
+0.16% (+706)
|
+0%
|
|
2023 Q2
|
2.18%
|
439,896
|
$94.33
|
$41,495,390
|
+6.01% (+24,921)
|
+0.12%
|
|
2023 Q1
|
2.07%
|
414,975
|
$82.73
|
$34,330,882
|
-2.63% (-11,198)
|
-0.06%
|
|
2022 Q4
|
1.97%
|
426,173
|
$74.61
|
$31,796,768
|
-0.94% (-4,023)
|
-0.02%
|
|
2022 Q3
|
2.41%
|
$82.63
|
+3.19% (+13,314)
|
|||
|
2022 Q2
|
2.61%
|
$95.09
|
+2.91% (+11,791)
|
|||
|
2022 Q1
|
2.69%
|
$117.72
|
-0.17% (-671)
|
|||
|
2021 Q4
|
2.80%
|
$129.55
|
+0.90% (+3,612)
|
|||
|
2021 Q3
|
2.71%
|
$113.21
|
-0.83% (-3,379)
|
|||
|
2021 Q2
|
2.55%
|
$103.57
|
+3.94% (+15,389)
|
|||
|
2021 Q1
|
2.18%
|
$83.64
|
+0.60% (+2,326)
|
|||
|
2020 Q4
|
2.71%
|
$91.23
|
+3.85% (+14,392)
|
|||
|
2020 Q3
|
2.73%
|
$79.82
|
+0.21% (+795)
|
|||
|
2020 Q2
|
2.56%
|
$69.11
|
+4.88% (+17,349)
|
|||
|
2020 Q1
|
2.84%
|
$62.87
|
-7.85% (-30,267)
|
|||
|
2019 Q4
|
2.71%
|
$77.76
|
+1.01% (+3,846)
|
|||
|
2019 Q3
|
2.79%
|
$73.30
|
+0.19% (+729)
|
|||
|
2019 Q2
|
2.37%
|
$61.58
|
+2.47% (+9,201)
|
|||
|
2019 Q1
|
2.72%
|
$63.78
|
+1.43% (+5,235)
|
|||
|
2018 Q4
|
2.47%
|
$51.06
|
-32.38% (-175,536)
|
|||
|
2018 Q3
|
3.56%
|
$58.03
|
+4.74% (+24,546)
|
|||
|
2018 Q2
|
3.27%
|
$48.52
|
+0.78% (+4,026)
|
|||
|
2018 Q1
|
3.20%
|
$46.51
|
+5.94% (+28,785)
|
|||
|
2017 Q4
|
2.50%
|
$37.57
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.